Personalis: Pay

Personalis paid its 3 named executives $6.7M in total in FY2025 (Dec). CEO Christopher Hall was paid $3.5M of that.

Pay$100 in the stock at the end of FY21 → $56
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Christopher HallChief Executive Officer and Director
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Aaron TachibanaChief Financial Officer and Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Richard Chen, M.D., M.S.President, Executive Vice President, Research and Development and Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 3 peers with pay on file was $4.3M. The CEO of Personalis was paid $3.5M, 19% below the median.

  1. 1GeneDx Holdings
  2. 2Pacific Biosciences Of California
  3. 3Personalis
  4. 4Outset Medical
  5. 5Adaptive Biotechnologies1Not disclosed
  6. 6Akoya Biosciences1Not disclosed
  7. 7Alector1Not disclosed
  8. 8BiodesixNot disclosed
  9. 9CareDx1Not disclosed
  10. 10Castle Biosciences1Not disclosed
  11. 11Codexis1Not disclosed
  12. 12CytomX Therapeutics1Not disclosed
  13. 13Fulgent Genetics1Not disclosed
  14. 14Mesa Laboratories1Not disclosed
  15. 15Nautilus BiotechnologyNot disclosed
  16. 16OraSure TechnologiesNot disclosed
  17. 17Quanterix1Not disclosed
  18. 18Seer1Not disclosed
  19. 19Standard BioTools1Not disclosed
  20. 20Sutro Biopharma1Not disclosed
  21. 21Twist Bioscience1Not disclosed
  22. 22Veracyte1Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.